PORTAGE PHARMACEUTICALS
Portage Pharmaceuticals LTD. is developing innovative cell permeable peptide (CPP) therapies to normalize gene expression, restore protein function, and improve medical outcomes. The Company has spun out its lead asset, PPL-003, to ophthalmic indications and has licensed this CellPorter technology to EyGen, a new ophthalmic company.
PORTAGE PHARMACEUTICALS
Industry:
Biopharma Biotechnology Pharmaceutical
Address:
Toronto, Ontario, Canada
Country:
Canada
Status:
Active
Similar Organizations
BioSentinel Pharmaceuticals
BioSentinel develops innovative tools and reagents for the study of botulinum neurotoxin (BoNT).
Kato Pharmaceuticals
Kato Pharmaceuticals is a clinical stage Bio-pharmaceutical company dedicated to the development of novel therapies for pathologies.
Kyowa Pharmaceutical
Kyowa Pharmaceutical is developing and marketing a wide range of branded and generic formulations of drugs in Japan.
Tavec pharma
Tavec Pharmaceuticals is developing injectable therapies to treat cancers.
More informations about "Portage Pharmaceuticals"
Home - Portage Biotech
Portage Biotech Inc. Clarence Thomas Building, P.0 Box 4649, Road Town, Tortola, British Virgin Islands, VG1110 203.221.7378 [email protected]See details»
Portage Biotech Inc. | CSE - Canadian Securities Exchange
Portage is a unique entity in the world of biotechnology, enabling research and development to produce more clinical programs and maximize potential returns by eliminating typical overhead …See details»
Investor Relations | Portage Biotech
Portage executes the development process and creates strategies to guide novel immuno-oncology assets as single agents and in combinations, from bench through human proof of …See details»
Portage Biotech Divests Portage Pharmaceuticals Limited to …
Mar 4, 2021 Toronto, Ontario--(Newsfile Corp. - March 4, 2021) - Portage Biotech Inc. (NASDAQ: PRTG) (CSE: PBT.U) ("Portage" or the "Company") a clinical stage immuno …See details»
Portage Biotech - Crunchbase Company Profile
Portage is engaged in researching and developing pharmaceutical and biotech products through to clinical "proof of concept" with an initial focus on unmet clinical needs. Following proof of concept, Portage will look to sell or license …See details»
PORTAGE BIOTECH INC.
Mar 4, 2021 PORTAGE BIOTECH DIVESTS PORTAGE PHARMACEUTICALS LIMITED TO JUVENESCENCE LTD - Out-licensing agreement facilitates focus on the Company’s immuno …See details»
Portage Pharmaceuticals - PitchBook
Portage Pharmaceuticals General Information Description. Developer of longevity-based therapies based in Tortola, British Virgin Islands. The company is involved in developing cell-permeable peptide (CPP) therapies to normalize …See details»
Juvenescence acquires Portage Pharmaceuticals - Crunchbase
Mar 4, 2021 Acquired Organization: Portage Pharmaceuticals Portage Pharmaceuticals is developing innovative cell permeable peptide (CPP) therapies to normalize gene expression.See details»
Portage BioTech Inc.: Exhibit 8.1 - Filed by newsfilecorp.com
Portage Pharmaceuticals Limited. BVI. 100% Stimunity S.A. France. 44% Portage Glasgow Limited. Scotland. 65% Portage Services Limited. Canada. ... 70% Intensity Holdings Ltd. BVI. …See details»
PORTAGE ‘s PPL FORMS A JOINT VENTURE WITH UNIVERSITY OF …
PORTAGE ‘s PPL FORMS A JOINT VENTURE WITH UNIVERSITY OF GLASGOW TO DEVELOP NEW PEPTIDE THERAPEUTICS. Toronto, Ontario, February 2, 2018 – Portage …See details»
Juvenescence scoops-up new longevity IP in smart acquisition
Mar 9, 2021 Portage Biotech Inc, a clinical-stage immuno-oncology company accelerating research and development to overcome immune resistance, has announced the divestment of …See details»
Portage Biotech Announces Plans to Expand its Evaluation of …
Apr 12, 2024 About Portage Biotech Inc. Portage is a clinical-stage immuno-oncology company advancing multi-targeted therapies to extend survival and significantly improve the lives of …See details»
Portage Biotech Company Profile - Office Locations, Competitors …
Apr 12, 2021 See insights on Portage Biotech including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. Advanced. Product. Solutions. ...See details»
Portage Biotech Divests Portage Pharmaceuticals Limited to
Mar 4, 2021 Toronto, Ontario--(Newsfile Corp. - March 4, 2021) - Portage Biotech Inc. (NASDAQ: PRTG) (CSE: PBT.U) (“Portage” or the “Company”) a clinical stage immuno …See details»
Portage announces spin-out of EyGen Limited - PR Newswire
Nov 30, 2016 Portage Biotech Inc.'s wholly owned subsidiary Portage Pharmaceuticals, Ltd. (PPL), having discovered CellPorter ®, a human-derived cell penetrating peptide platform for …See details»
Portage Pharmaceuticals - Crunchbase
Portage Pharmaceuticals is developing innovative cell permeable peptide (CPP) therapies to normalize gene expression.See details»
Portage previews possible closure as it hunts for options - Fierce …
Apr 12, 2024 Portage reported having about $5 million in cash on hand as of the end of 2023. Portage Biotech is putting the clamps on existing work to save cash as it prioritizes a hunt for …See details»
Portage Biotech Divests Portage Pharmaceuticals Limited to …
Mar 3, 2021 Portage may be entitled to up to USD $244 million in future milestone payments -Toronto, ... Portage Pharmaceuticals Limited including subsidiaries Portage Glasgow Ltd. and …See details»
Portage Announces Spin-Out of EyGen Limited | American …
Nov 30, 2016 Portage Biotech Inc.'s wholly owned subsidiary Portage Pharmaceuticals, Ltd. (PPL), having discovered CellPorter ®, a human-derived cell penetrating peptide platform for …See details»
Canada’s complicated drug-approval system needs overhaul, …
6 days ago Doug Clark is calling for reform to Canada’s byzantine drug regulation system. Mr. Clark, former executive director of the Patented Medicine Prices Review Board (PMPRB), in …See details»